Recombinant Human MIF protein

• Cat.No.: MIF-4742H
• Product Overview: Recombinant Human MIF protein was expressed in Escherichia coli.

Specification

• Description: Migration Inhibitory Factor (MIF) is a secreted protein without a cleavable signal sequence and is secreted via a specialized, non-classical pathway. It is secreted by macrophages upon stimulation by bacterial lipopolysaccharide (LPS), or by M.tuberculosis antigens. MIF consists of two α-helices and six β-strands, four of which form a β-sheet. The two remaining β-strands interact with other MIF molecules, creating a trimer. Structure-function studies suggest MIF is bifunctional with segregated topology. The N- and C-termini mediate enzyme activity (in theory). Phenylpyruvate tautomerase activity (enol-to-keto) has been demonstrated and is dependent upon Pro at position 1. Amino acids 50-65(a.a.) have also been suggested to contain thiol-protein oxidoreductase activity. MIF has proinflammatory cytokine activity centered around (a.a.) 49 - 65. On fibroblasts, MIF induces, IL-1, IL-8 and MMP expression; on macrophages, MIF stimulates NO production and TNF-α release folllowing IFN-γ activation. MIF apparently acts through CD74 and CD44, likely in some form of trimeric interaction. Human MIF is active on mouse cells. Human MIF is 90%, 94%, 95%, and 90% aa identical to mouse, bovine, porcine and rat MIF, respectively.
• Source: E.coli
• Species: Human
• Form: Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.4.
• Bio-activity: Fully biologically active when compared to standard. The specific activity is determined by binding rhCD74 in a functional ELISA.
• Molecular Mass: Approximately 12.5 kDa, a single non-glycosylated polypeptide chain containing 115 amino acids.
• Protein length: 115
• AA Sequence: MPMFIVNTNVPRASVPDGFLSELTQ QLAQATGKPPQYIAVHVVPDQLMAF GGSSEPCALCSLHSIGKIGGAQNRS YSKLLCGLLAERLRISPDRVYINYY DMNAANVGWNNSTFA
• Endotoxin: Less than 1 EU/µg of rHuMIF as determined by LAL method.
• Purity: >97% by SDS-PAGE and HPLC analysis.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions.
• Tag: Non

Gene Information

• Gene Name: MIF
• Official Symbol: MIF
• Synonyms: MIF; macrophage migration inhibitory factor (glycosylation-inhibiting factor); GLIF; macrophage migration inhibitory factor; GIF; L-dopachrome isomerase; L-dopachrome tautomerase; phenylpyruvate tautomerase; MMIF
• Gene ID: 4282
• mRNA Refseq: NM_002415
• Protein Refseq: NP_002406
• MIM: 153620
• UniProt ID: P14174

Reviews

12/05/2022

The cost-effectiveness of the MIF protein, competitive pricing, and the availability of bulk purchase options provided by the manufacturer also align with my budget considerations, allowing me to optimize my resources.

10/13/2016

the manufacturer's commitment to delivering the MIF protein in a timely manner is greatly appreciated.

06/06/2016

the excellent technical support provided by the manufacturer is of immense value to me.

Q&As

How does MIF contribute to autoimmune diseases?

MIF can promote inflammation and immune responses, contributing to autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.

How does MIF influence neuroinflammation?

MIF is involved in the regulation of neuroinflammation and has implications in neurodegenerative diseases like Alzheimer's.

What are some conditions where MIF is implicated in clinical applications?

MIF is implicated in conditions like autoimmune diseases, sepsis, and cancer.

Can MIF be a potential therapeutic target in autoimmune diseases?

Yes, targeting MIF with drugs or antibodies is being explored as a potential treatment for autoimmune diseases.

What are some other clinical applications of MIF?

MIF is also studied in the context of cardiovascular diseases, neuroinflammation, and wound healing.